Skip to main content

2022 Award WinnerDavid Burns

NIAID (National Institute of Allergy and Infectious Diseases)

Scientific/Medical

Scientific/Medical Group Awards

HPTN 083 & HPTN 084 Clinical Trial Team

In recognition of exceptional conduct of the HPTN 083 & HPTN 084 clinical trials that resulted in FDA approval of Cabotegravir Long Acting (CAB LA).